Chongzhao Ran, PhD
Assistant Professor in Radiology, Harvard Medical School
Assistant in Neuroscience, Massachusetts General Hospital
PhD Medicinal Chemistry, Shanghai Institute of Pharmaceutical Industry, China, 2000
Building 149, Room 2301
Charlestown, MA 02129 USA
General Contact Information
Disease. At present, the few agents approved by the FDA and the clinical
candidates have demonstrated only a modest effect, and none has shown a clear
effect on disease progression or prevention.
It is widely believed that the best treatment/prevention time window is
at a presymptomatic stage, because the molecular pathological abnormality
starts at about 5-15 years before the onset of the clinical symptoms. Clearly,
early diagnosis of AD at its presymptomatic stage is tremendously desirable.
My research is structured to seek molecular
imaging probes capable of detecting Amyloidosis (the most important molecular
pathology of AD) within its full molecular pathological course. This process
probably starts from imbalanced accumulation of amyloid beta monomers, and ends with large plaques and
neuron death. In order to achieve this goal, my research has been focused on 1)
Fluorescent imaging probe development; 2) Multi-modal imaging of AD; 3)
Advanced fluorescence molecular imaging for AD; and 4) Imaging-based drug
discovery for AD. For more details, please see the link below.